论文部分内容阅读
目的:探讨IHCP+CDS治疗晚期子宫内膜癌的临床疗效和安全性。方法:选取治疗确诊为晚期子宫内膜癌的患者84例,随机分为观察组和对照组。观察组采用IHCP+CDS方案化疗,对照组采用常规灌注+肿瘤细胞减灭术方案化疗。比较两组的手术时间、临床疗效、复发率、生存时间和不良反应等。结果:观察组手术时间和术中腹水量比对照组少,两组差异明显(P<0.05);观察组总有效率和24个月生存率比对照组高,而复发率比对照组低(P<0.05);观察组恶心、麻木发生率较对照组低(P<0.05);而白细胞降低、血小板降低和盆腔感染方面相互比较,无显著差异(P>0.05)。结论:IHCP+CDS能有效改善晚期子宫内膜癌患者术前和术后对化疗的耐受性;提高患者的生存率和临床治疗效果。
Objective: To investigate the clinical efficacy and safety of IHCP + CDS in the treatment of advanced endometrial carcinoma. Methods: Eighty-four patients with advanced endometrial cancer were selected and randomly divided into observation group and control group. The observation group was treated with IHCP + CDS chemotherapy, while the control group was treated with conventional perfusion + cytoreductive surgery. The operation time, clinical efficacy, relapse rate, survival time and adverse reactions of the two groups were compared. Results: The operation time and intraoperative ascites volume in the observation group were less than those in the control group (P <0.05). The total effective rate and the 24-month survival rate in the observation group were higher than those in the control group, but the recurrence rate was lower (P <0.05). The incidence of nausea and numbness in the observation group was lower than that in the control group (P <0.05). There was no significant difference between the observation group and the control group (P <0.05). Conclusion: IHCP + CDS can effectively improve the patients with advanced endometrial cancer before and after chemotherapy tolerance; improve patient survival and clinical treatment.